A. J. Robert McGray
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
A. J. Robert McGray has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Bryan M. Gillard
Roswell Park Comprehensive Cancer Center 1 Buffalo, NY
14 shared publications - Jason H. Tong
Roswell Park Comprehensive Cancer Center 1 Department of Immunology Buffalo, New York
14 shared publications - Jonathan L. Bramson
Department of Medicine, McMaster University, Hamilton, Canada
14 shared publications - Mackenzie M. Lieberman
Roswell Park Comprehensive Cancer Center 1 Department of Immunology Buffalo, New York
14 shared publications - Rebecca Burchett
McMaster University 3 Department of Pathology and Molecular Medicine, McMaster Immunology Research Centre Hamilton, Canada
14 shared publications - Scott H. Olejniczak
Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA
14 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Pivot Science Publications Corporation in Cancer Heterogeneity and Plasticity
- Vol. 3 (3)
When immune landscapes diverge: How immune cell heterogeneity shapes cancer immunotherapy response
Amplifying the antitumor immune response using immunotherapy has significantly improved patient survival and transformed cancer care. Findings from preclinical studies as well as clinical observations have firmly established that the intratumoral accumulation of T cells often serves as a positive predictor of immunotherapy response. While this observation has led to the commonly used “cold or hot” classifiers to describe the T cell landscape within a tumor, this is increasingly being recognized as an oversimplification. Instead, there is a growing appreciation for the broader composition, spatial localization, and dynamic nature of the tumor immune landscape across cancer types. In this perspective, we describe the diverse and unique immune correlates that have been associated with response (or lack thereof) following immunotherapy. Beginning with our own published findings related to the heterogeneous immune landscapes associated with divergent responses to adoptive T cell therapy combined with immune checkpoint inhibition, we then overlay key observations from other recently published studies to highlight the impact of the broader immune landscape in determining treatment outcome. Finally, we recommend leveraging modern multi-omic analysis tools prior to and during immunotherapy treatment to define immune signatures associated with favorable response, those that can predict treatment outcome, or which can be leveraged to identify complementary therapeutic approaches.
- 10 July 2026
- Published by Pivot Science Publications Corporation in Cancer Heterogeneity and Plasticity
- Vol. 3 (3)
Open AccessWhen immune landscapes diverge: How immune cell heterogeneity shapes cancer immunotherapy response
Amplifying the antitumor immune response using immunotherapy has significantly improved patient survival and transformed cancer care. Findings from preclinical studies as well as clinical observations have firmly established that the intratumoral accumulation of T cells often serves as a positive predictor of immunotherapy response. While this observation has led to the commonly used “cold or hot” classifiers to describe the T cell landscape within a tumor, this is increasingly being recognized as an oversimplification. Instead, there is a growing appreciation for the broader composition, spatial localization, and dynamic nature of the tumor immune landscape across cancer types. In this perspective, we describe the diverse and unique immune correlates that have been associated with response (or lack thereof) following immunotherapy. Beginning with our own published findings related to the heterogeneous immune landscapes associated with divergent responses to adoptive T cell therapy combined with immune checkpoint inhibition, we then overlay key observations from other recently published studies to highlight the impact of the broader immune landscape in determining treatment outcome. Finally, we recommend leveraging modern multi-omic analysis tools prior to and during immunotherapy treatment to define immune signatures associated with favorable response, those that can predict treatment outcome, or which can be leveraged to identify complementary therapeutic approaches.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 7 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
CD86 expression on patient MM cells prior to CAR T therapy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 7 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
CD86 expression on patient MM cells prior to CAR T therapy.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 3 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of CAR T cell mitochondrial metabolism.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 3 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of CAR T cell mitochondrial metabolism.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Key Resources Table 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Key Resources Table 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessKey Resources Table 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Key Resources Table 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 8 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Effect of transient abatacept exposure on MM.1S growth.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 8 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Effect of transient abatacept exposure on MM.1S growth.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 2 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of human and mouse CD28 knockout CAR T cells, and mouse myeloma target cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 2 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of human and mouse CD28 knockout CAR T cells, and mouse myeloma target cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 6 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of short duration of CD28 blockade in mice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 6 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of short duration of CD28 blockade in mice.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 5 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
In vivo CAR T cell characterization.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 5 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
In vivo CAR T cell characterization.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of human hBCMABBζ CAR T cells and myeloma target cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of human hBCMABBζ CAR T cells and myeloma target cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Gating Strategies 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Gating strategies used to identify cell populations of interest.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Gating Strategies 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Gating strategies used to identify cell populations of interest.